Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Breast Neoplasms 2Sarcoma 1Neuroblastoma 1Lymphoma 1Leukemia 1Central Nervous System Neoplasms 1Cardiotoxicity 1

Interventions

Cyclophosphamide 227Cytarabine 194fludarabine phosphate 138Methotrexate 132Filgrastim 127Busulfan 103Etoposide 99Peripheral Blood Stem Cell Transplantation 91Rituximab 81fludarabine 77Radiotherapy 77Vincristine 74Daunorubicin 68Antilymphocyte Serum 65Cyclosporine 63Dexamethasone 61Tacrolimus 56Mycophenolic Acid 53Melphalan 52Imatinib Mesylate 50Granulocyte Colony-Stimulating Factor 50Mercaptopurine 46Whole-Body Irradiation 45Idarubicin 43sargramostim 42Methylprednisolone 42Doxorubicin 41Flow Cytometry 40Prednisone 39Clofarabine 39

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia × Fenofibrate × Clear all
NCT00357500 2014-10-01

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
101 enrolled 10 charts
CNSLymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neuroblastoma, Sarcoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡